Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Aclaris Therapeutics	Lexicon Pharmaceuticals	Syndax Pharmaceuticals	Five Prime Therapeutics	Phibro Animal Health
Symbol	NASDAQ:ACRS	NASDAQ:LXRX	NASDAQ:SNDX	NASDAQ:FPRX	NASDAQ:PAHC
Price Information
Current Price	$27.75	$5.12	$21.03	$37.95	$23.96
52 Week Range	N/A	Hold	Buy	Hold	Hold
MarketRank™
Overall Score	0.8	1.6	1.6	1.4	1.8
Analysis Score	0.0	3.1	3.4	2.1	0.8
Community Score	2.6	2.5	2.5	2.7	2.2
Dividend Score	0.0	0.0	0.0	0.0	2.5
Ownership Score	0.8	1.7	1.7	1.7	1.7
Earnings & Valuation Score	0.6	0.6	0.6	0.6	1.9
Analyst Ratings
Consensus Recommendation	N/A	Hold	Buy	Hold	Hold
Consensus Price Target	N/A	$9.40	$28.55	$30.71	$21.50
% Upside from Price Target	N/A	83.59% upside	35.74% upside	-19.07% downside	-10.27% downside
Trade Information
Market Cap	$1.50 billion	$775.18 million	$1.07 billion	$1.77 billion	$992.72 million
Beta	1.2	2.09	1.8	4.4	0.46
Average Volume	2,806,437	4,668,547	672,293	2,047,596	144,758
Sales & Book Value
Annual Revenue	$4.23 million	$322.07 million	$1.52 million	$14.87 million	$800.40 million
Price / Sales	339.85	2.29	667.37	118.86	1.21
Cashflow	N/A	$2.30 per share	N/A	N/A	$2.16 per share
Price / Cash	N/A	2.23	N/A	N/A	11.10
Book Value	$1.69 per share	$1.10 per share	$1.16 per share	$4.13 per share	$4.65 per share
Price / Book	16.42	4.65	18.13	9.19	5.15
Profitability
Net Income	$-161,350,000.00	$130.13 million	$-56,050,000.00	$-137,200,000.00	$33.55 million
EPS	($2.25)	$1.35	($1.84)	($3.92)	$1.08
Trailing P/E Ratio	N/A	N/A	N/A	N/A	22.60
Forward P/E Ratio	N/A	N/A	N/A	N/A	21.20
P/E Growth	N/A	N/A	N/A	N/A	2.00
Net Margins	-941.07%	-320.44%	-4,656.63%	-554.71%	5.37%
Return on Equity (ROE)	-104.00%	-164.96%	-77.47%	-75.84%	23.70%
Return on Assets (ROA)	-64.47%	-31.83%	-52.27%	-49.08%	5.99%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	$0.48
Dividend Yield	N/A	N/A	N/A	N/A	2.00%
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	20.00%
Payout Ratio	N/A	N/A	N/A	N/A	44.44%
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	1 Years
Debt
Debt-to-Equity Ratio	0.26%	0.13%	0.15%	N/A	1.97%
Current Ratio	4.54%	1.54%	11.71%	5.35%	2.88%
Quick Ratio	4.54%	1.55%	11.71%	5.35%	1.61%
Ownership Information
Institutional Ownership Percentage	59.10%	84.62%	83.78%	67.28%	50.32%
Insider Ownership Percentage	8.20%	6.40%	9.50%	6.40%	50.05%
Miscellaneous
Employees	57	78	43	87	1,700
Shares Outstanding	51.80 million	144.35 million	48.24 million	46.57 million	40.45 million
Next Earnings Date	5/6/2021 (Estimated)	4/26/2021 (Estimated)	5/6/2021 (Estimated)	5/6/2021 (Estimated)	5/6/2021 (Confirmed)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Phibro Animal Health Corporation to Host Webcast and Conference Call on March 2021 Quarterly Financial Results finance.yahoo.com - April 8 at 6:32 PM
	Phibro Animal Health Corporation to Participate in Bank of America Securities 2021 Virtual Healthcare Conference finance.yahoo.com - April 7 at 7:34 PM
	PAHC or SRDX: Which Is the Better Value Stock Right Now? finance.yahoo.com - April 7 at 2:14 PM
	Phibro Animal Health (PAHC) forbes.com - March 19 at 10:54 AM
	Head-To-Head Review: Phibro Animal Health (NASDAQ:PAHC) vs. MorphoSys (NASDAQ:MOR) americanbankingnews.com - March 18 at 8:18 AM
	Why Is Phibro (PAHC) Up 1.1% Since Last Earnings Report? finance.yahoo.com - March 5 at 2:29 PM
	Phibro Animal Health Corporation to Participate in the Barclays Virtual Global Healthcare Conference finance.yahoo.com - February 8 at 5:48 PM
	Phibro Animal Health Corporation to Participate in Bank of America Merrill Lynch 2021 Virtual Animal Health Summit finance.yahoo.com - February 8 at 12:47 PM
	Phibro Animal Health Corporation Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next nasdaq.com - February 5 at 9:43 AM
	Phibro Animal Health Corp (PAHC) Q2 2021 Earnings Call Transcript finance.yahoo.com - February 4 at 11:43 PM
	Phibro Animal Health A is about to announce earnings — here's what Wall Street expects markets.businessinsider.com - February 2 at 7:45 PM
	PAHC vs. SRDX: Which Stock Should Value Investors Buy Now? finance.yahoo.com - January 20 at 4:26 PM
	Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails finance.yahoo.com - January 12 at 11:09 AM
	Phibro Animal Health Corporation to Host Webcast and Conference Call on December 2020 Quarterly Financial Results finance.yahoo.com - January 5 at 7:46 PM
	Why Phibro Animal Health Corporation (NASDAQ:PAHC) Looks Like A Quality Company finance.yahoo.com - December 25 at 3:00 PM
	Phibro Animal Health: Not Overly Expensive At 10X Its EBITDA seekingalpha.com - December 16 at 12:45 PM
	Is PAHC A Good Stock To Buy Now? finance.yahoo.com - December 16 at 1:18 AM
	Why Is Phibro (PAHC) Up 1.4% Since Last Earnings Report? finance.yahoo.com - December 4 at 5:55 PM
	Phibro (PAHC) Hurt by Adverse Pricing in Mineral Nutrition Arm finance.yahoo.com - November 24 at 12:32 PM
	An Intrinsic Calculation For Phibro Animal Health Corporation (NASDAQ:PAHC) Suggests It's 49% Undervalued finance.yahoo.com - November 9 at 5:31 PM
	Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - November 7 at 12:43 AM
	Phibro: Fiscal 1Q Earnings Snapshot chron.com - November 5 at 8:22 AM
	Phibro Animal Health Corp (A) hosts conference call for investors markets.businessinsider.com - November 4 at 7:17 PM
	How Is Phibro Animal Health's (NASDAQ:PAHC) CEO Paid Relative To Peers? uk.news.yahoo.com - October 2 at 1:49 PM
	Phibro Animal Health Corporation to Host Webcast and Conference Call on September 2020 Quarterly Financial Results benzinga.com - October 1 at 6:49 PM

Date	Company	Brokerage	Action
1/2/2020	Aclaris Therapeutics	SVB Leerink	Reiterated Rating
10/11/2019	Aclaris Therapeutics	William Blair	Reiterated Rating
9/6/2019	Aclaris Therapeutics	JMP Securities	Downgrade
8/9/2019	Aclaris Therapeutics	Cantor Fitzgerald	Reiterated Rating
1/29/2021	Lexicon Pharmaceuticals	Wedbush	Downgrade
1/29/2021	Lexicon Pharmaceuticals	JPMorgan Chase & Co.	Upgrade
1/15/2021	Lexicon Pharmaceuticals	G.Research	Downgrade
1/15/2021	Lexicon Pharmaceuticals	Citigroup	Boost Price Target
1/15/2021	Lexicon Pharmaceuticals	Gabelli	Downgrade
1/14/2021	Lexicon Pharmaceuticals	Smith Barney Citigroup	Boost Price Target
12/8/2020	Lexicon Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade
4/27/2020	Lexicon Pharmaceuticals	Needham & Company LLC	Reiterated Rating
2/18/2021	Syndax Pharmaceuticals	B. Riley	Initiated Coverage
12/7/2020	Syndax Pharmaceuticals	Morgan Stanley	Boost Price Target
12/7/2020	Syndax Pharmaceuticals	BTIG Research	Boost Price Target
12/7/2020	Syndax Pharmaceuticals	Barclays	Boost Price Target
12/2/2020	Syndax Pharmaceuticals	Stifel Nicolaus	Initiated Coverage
5/25/2020	Syndax Pharmaceuticals	Nomura	Reiterated Rating
5/22/2020	Syndax Pharmaceuticals	HC Wainwright	Downgrade
4/28/2020	Syndax Pharmaceuticals	Robert W. Baird	Boost Price Target
3/26/2020	Syndax Pharmaceuticals	Nomura Securities	Reiterated Rating
3/15/2021	Five Prime Therapeutics	Guggenheim	Reiterated Rating
3/10/2021	Five Prime Therapeutics	Jefferies Financial Group	Reiterated Rating
3/4/2021	Five Prime Therapeutics	Roth Capital	Downgrade
3/4/2021	Five Prime Therapeutics	Wells Fargo & Company	Downgrade
8/12/2020	Five Prime Therapeutics	Cowen	Reiterated Rating
5/8/2020	Phibro Animal Health	Credit Suisse Group	Lower Price Target
8/29/2019	Phibro Animal Health	Bank of America	Lower Price Target

(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources